Enzo Biochem (ENZ) Appoints Steven J. Pully to its Board

Enzo Biochem, Inc. (NYSE: ENZ) announced today that Steven J. Pully has been appointed to the Company’s Board of Directors effective October 26, 2023. Mr. Pully will assume the role of Chairperson of the Board, and Chair of the Audit Committee as well.

“In 2023, Enzo completed the divestiture of Enzo Clinical Labs, Inc. and focused its strategy on growing the life sciences division,” said Kara Cannon, Enzo’s Chief Executive Officer. “Steve brings a unique portfolio of legal, corporate governance, and financial skills to our Board of Directors, and his experience will facilitate his work with the board members and management to implement our focused growth and operational strategy. He is highly-respected and experienced in working with companies and investors across many different industries and in a number of different roles. He has served on boards of many public and private companies and as a corporate officer. He will play a central role in our continued success and the future growth at Enzo.”

Mr. Pully is currently a partner of Speyside Partners, an investment banking firm that he co-founded in May 2017. He also serves on the boards or in executive positions for various companies, including publicly-traded RumbleOn, Inc., where he serves as the Executive Chairman. Mr. Pully’s board service has spanned multiple industries, including airlines, amusement parks, energy and power, manufacturing, power sports, retail, restaurants, and technology. His board service has included multiple positions as chairman or lead director of the board, and also multiple chairmanships of audit, compensation, nominating and governance, and special committees. Previously, Mr. Pully served as General Counsel and as a Partner of the investment firm, Carlson Capital, L.P. from 2008 to 2014, as Managing Director in the investment banking division of Bank of America and as a Senior Managing Director in the investment banking department of Bear Stearns & Company. Mr. Pully is also an attorney and CPA, he is a Chartered Financial Analyst, and he also holds various FINRA licenses.

“I am very pleased to be joining the Enzo Board of Directors at a time that presents so many important opportunities for the Company to continue to show innovation and leadership as it continues to develop and grow its Life Sciences division,” said Mr. Pully. “I look forward to working closely with the members of the board and the Enzo leadership team to maximize the full range of business opportunities the Company is targeting in the years ahead.”

You May Also Be Interested In

• Primis Financial adds Margaret Weichert to its board
• AEVEX names Murali Krishnan as chief growth officer
• Chip stocks hit record 19.7% of S&P 500, quadrupling since 2020